InvestSMART

Syntara Limited (ASX:SNT)

ALERT: Price-sensitive ASX Announcement for SNT
Current share price for SNT : $0.026 0.003 (13.04%)+
Announcement
Release
6 Jul 2026 9:43AM
Price at Release
$0.023
Full Release
download
Summary
Syntara Limited announced encouraging preliminary results from its Phase 2 study of SNT-4728, a neuro-targeted anti-inflammatory therapy for patients with isolated REM Sleep Behaviour Disorder (iRBD), a condition linked to the development of Parkinson’s Disease. The study showed a statistically significant reduction in brain inflammation in the putamen, a brain region associated with motor symptoms of Parkinson’s. The trial involved 41 patients and used Positron Emission Tomography (PET) imaging to assess neuroinflammation. SNT-4728 was well tolerated, with no serious adverse events reported. This research adds potential for slowing the progression to Parkinson’s and has led to a new provisional patent application. Full results, including further analyses, are expected in late Q3 2026.
Key Points
  • First interventional study targeting neuroinflammation in iRBD to reduce progression to Parkinson’s.
  • Statistically significant reduction in brain inflammation in the putamen.
  • PET imaging used to monitor neuroinflammation.
  • SNT-4728 was well tolerated with no serious adverse events.
  • Potential to slow progression to Parkinson’s Disease.
  • New provisional patent application filed based on results.
  • Full results expected in Q3 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.